Directive 2002/98 - Standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components

Please note

This page contains a limited version of this dossier in the EU Monitor.

1.

Current status

This directive is in effect from February  8, 2003 until August  6, 2027 and should have been implemented in national regulation on February  8, 2005 at the latest.

2.

Key information

official title

Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC
 
Legal instrument Directive
Number legal act Directive 2002/98
Original proposal COM(2000)816 EN
CELEX number i 32002L0098

3.

Key dates

Document 27-01-2003
Publication in Official Journal 08-02-2003; Special edition in Slovenian: Chapter 15 Volume 007,Special edition in Romanian: Chapter 15 Volume 009,Special edition in Bulgarian: Chapter 15 Volume 009,Special edition in Latvian: Chapter 15 Volume 007,Special edition in Czech: Chapter 15 Volume 007,Special edition in Lithuanian: Chapter 15 Volume 007,Special edition in Hungarian: Chapter 15 Volume 007,Special edition in Croatian: Chapter 15 Volume 012,Special edition in Slovak: Chapter 15 Volume 007,Special edition in Polish: Chapter 15 Volume 007,Special edition in Maltese: Chapter 15 Volume 007,Special edition in Estonian: Chapter 15 Volume 007,OJ L 33, 8.2.2003
Effect 08-02-2003; Entry into force Date pub. See Art 33
End of validity 06-08-2027; Repealed by 32024R1938
Transposition 08-02-2005; At the latest See Art 32.1

4.

Legislative text

Avis juridique important

|

5.

32002L0098

Directive 2002/98/EC of the European Parliament and of the Council of 27 January 2003 setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC

Official Journal L 033 , 08/02/2003 P. 0030 - 0040

Directive 2002/98/EC of the European Parliament and of the Council

of 27 January 2003

setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components and amending Directive 2001/83/EC

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty establishing the European Community, and in particular Article 152(4)(a) thereof,

Having regard to the proposal from the Commission(1),

Having regard to the opinion of the Economic and Social Committee(2),

Having regard to the opinion of the Committee of the Regions(3),

Acting in accordance with the procedure laid down in Article 251 of the Treaty(4), in the light of the joint text approved by the Conciliation Committee on 4 November 2002,

Whereas:

  • (1) 
    The extent to which human blood is used therapeutically demands that the quality and safety of whole blood and blood components be ensured in order to prevent in particular the transmission of diseases.
  • (2) 
    The availability of blood and blood components used for therapeutic purposes is dependent largely on Community citizens who are prepared to donate. In order to safeguard public health and to prevent the transmission of infectious diseases, all precautionary measures during their collection, processing, distribution and use need to be taken making appropriate use of scientific progress in the detection and inactivation and elimination of transfusion transmissible pathogenic agents.
  • (3) 
    The quality, safety, and efficacy requirements of proprietary industrially-prepared medicinal products derived from human blood or plasma were ensured through Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use(5). The specific exclusion of whole blood, plasma and blood cells of human origin from that Directive, however, has led to a situation whereby their quality and safety, in so far as they are intended for transfusion and not processed as such, are not subject to any binding Community legislation. It is essential, therefore, that whatever the intended purpose, Community provisions should ensure that blood and its components are of comparable quality and safety throughout the blood transfusion chain in all Member States, bearing in mind the freedom of movement of citizens within Community territory. The establishment of high standards of quality and safety, therefore, will help to reassure the public that human blood and blood components which are derived from donations in another Member State nonetheless meet the same requirements as those in their own country.
  • (4) 
    In respect of blood or blood components as a starting material for the manufacture of proprietary medicinal products, Directive 2001/83/EC refers to measures to be taken by Member States to prevent the transmission of infectious diseases, comprising the application of the monographs of the European Pharmacopoeia and the recommendations of the Council of Europe and the World Health Organisation (WHO) as regards in particular the selection and testing of blood and plasma donors. Furthermore, Member States should take measures to promote Community self-sufficiency in human blood or blood components and to encourage voluntary unpaid donations of blood and blood components.
  • (5) 
    In order to ensure that there is an equivalent level of safety and quality of blood components, whatever their intended purpose, technical requirements for the collection...

More

This text has been adopted from EUR-Lex.

6.

Original proposal

 

7.

Sources and disclaimer

For further information you may want to consult the following sources that have been used to compile this dossier:

This dossier is compiled each night drawing from aforementioned sources through automated processes. We have invested a great deal in optimising the programming underlying these processes. However, we cannot guarantee the sources we draw our information from nor the resulting dossier are without fault.

 

8.

Full version

This page is also available in a full version containing the summary of legislation, de geconsolideerde versie, the legal context, de Europese rechtsgrond, other dossiers related to the dossier at hand, the related cases of the European Court of Justice and finally consultations relevant to the dossier at hand.

The full version is available for registered users of the EU Monitor by ANP and PDC Informatie Architectuur.

9.

EU Monitor

The EU Monitor enables its users to keep track of the European process of lawmaking, focusing on the relevant dossiers. It automatically signals developments in your chosen topics of interest. Apologies to unregistered users, we can no longer add new users.This service will discontinue in the near future.